Oculis (NASDAQ:OCS) Stock Price Up 7.2% – Here’s Why

Oculis Holding AG (NASDAQ:OCS) shares rose 7.2% during trading on Wednesday . The stock traded as high as $12.87 and last traded at $13.1750. Approximately 948,993 shares changed hands during trading, an increase of 101% from the average daily volume of 472,034 shares. The stock had previously closed at $12.29.

Wall Street Analyst Weigh In

OCS has been the subject of several analyst reports. HC Wainwright lowered their target price on Oculis from $47.00 to $26.00 and set a “buy” rating for the company in a research note on Monday. JPMorgan Chase & Co. lowered their target price on Oculis from $42.00 to $23.00 and set an “overweight” rating for the company in a research note on Wednesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oculis in a research report on Tuesday, April 21st. Guggenheim lowered their price objective on Oculis from $75.00 to $45.00 and set a “buy” rating for the company in a research report on Monday. Finally, Wall Street Zen cut Oculis from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. Nine investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $38.33.

Oculis Trading Up 8.2%

The company has a 50-day moving average price of $27.46 and a 200-day moving average price of $25.18. The firm has a market capitalization of $771.19 million, a price-to-earnings ratio of -6.26 and a beta of 0.23. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.18 and a current ratio of 5.18.

Oculis (NASDAQ:OCS) last released its quarterly earnings data on Friday, May 8th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.14). The business had revenue of $0.26 million for the quarter, compared to analyst estimates of $0.25 million. Oculis had a negative return on equity of 56.78% and a negative net margin of 8,460.67%. As a group, research analysts forecast that Oculis Holding AG will post -2.21 EPS for the current fiscal year.

Institutional Trading of Oculis

A number of large investors have recently made changes to their positions in the company. Bank of America Corp DE boosted its position in shares of Oculis by 9.1% in the 1st quarter. Bank of America Corp DE now owns 69,764 shares of the company’s stock valued at $1,855,000 after purchasing an additional 5,813 shares during the period. Himension Capital Singapore PTE. LTD. acquired a new stake in shares of Oculis in the 1st quarter valued at about $503,000. Koshinski Asset Management Inc. acquired a new stake in shares of Oculis in the 1st quarter valued at about $238,000. Y Intercept Hong Kong Ltd acquired a new stake in shares of Oculis in the 1st quarter valued at about $776,000. Finally, Perceptive Advisors LLC acquired a new stake in shares of Oculis in the 4th quarter valued at about $9,862,000. 22.30% of the stock is owned by institutional investors and hedge funds.

Oculis Company Profile

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.